Kornimate/medical-research-clean huggingface dataset:
internet-delivered treatment for children with anxiety disorders in a rural area; an open trial in a clinical setting

Conditions: Specific Phobia; Separation Anxiety; Generalized Anxiety Disorder

Summary: an open trial will be conducted at the child and mental health service (camhs) unit in the rural county jämtland in sweden to test the feasibility and efficacy of internet-delivered cognitive behavior therapy (icbt) for children with anxiety disorders in a clinical setting. 20 children with a principal diagnosis of generalized anxiety disorder (gad), separation anxiety, specific phobia and their parents will be recruited from the camhs-center in östersund. they will receive 12 weeks of therapist-supported icbt and will be assessed by clinician ratings and child- and parent-reports at baseline, post-treatment and 3 month follow-up. the primary outcome measures the clinical global impressions - severity scale (cgi-s). secondary outcome measures include clinician rated global functioning, and child and parent-rated anxiety and functioning.


Eligibility criteria:
inclusion criteria: * 8-12 years of age * fulfilling diagnostic criteria for generalized anxiety disorder (gad), separation anxiety, specific phobia * ability to read and write swedish * daily access to the internet * a parent that is able to co-participate in the treatment * participants on psychotropic medication must have been on a stable dose for the last 3 months prior to baseline assessment exclusion criteria: * diagnosed autism spectrum disorder or attention-deficit/hyperactivity disorder (adhd), or principal primary disorder other than gad, separation anxiety, specific phobia * acute/severe psychiatric problems such as suicidal risk or severe depression * ongoing psychological treatment for anxiety disorders * ongoing child custody dispute or abuse in the family
vaccination for children of h&o and their parents

Conditions: Vaccination; Hematologic Malignancy; Solid Tumor, Childhood

Summary: the purpose of this study is to study on compliance, safety and effectivity of vaccination for children with hematologic malignancies or solid tumors and their parents.

children with hematologic malignancies or solid tumors are all facing with immune deficiency due to the disease, the chemotherapy, the hematopoietic stem cell transplantation or the splenectomy, which greatly increases their chance to get infectious diseases. in this study, we will assess the compliance of children with hematologic malignancies or solid tumors and their parents to accept vaccination after finishing treatments, follow up with untoward effect questionnaires to assess the safety, obtain the serum of children patients to test antibody titers and assess the effectivity, provide clues for the study of vaccination in children with hematologic malignancies or solid tumors and provide a scientific basis for the formulation and reunification of vaccination programs.

Eligibility criteria:
inclusion criteria: 1. children patients(≤18 years) who accepted chemotherapy, hematopoietic stem cell transplantation or splenectomy since our study started. 2. no history of hepatitis b and measles, do not suffer from other diseases that affect immune function and allergic diseases. exclusion criteria: 1. children patients who did not reach clinical remission after treatment, critically ill or eventually died. 2. patients who used monoclonal antibodies, especially anti-tumor necrosis factors. 3. intermittent or low-dose chemotherapy or other immunosuppressive drugs users.

Keywords: vaccination childhood hematologic malignancy solid tumor immune deficiency
therapeutic study of ono-4819cd for ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to investigate whether ono-4819cd is safe and effective in the treatment of mild to moderate ulcerative colitis.

ulcerative colitis is a relapsing disease of unknown cause characterized by bloody diarrhea. therapy usually involves 5-aminosalicylates, corticosteroids and immunosuppressants. however, steroid resistance and dependency can become problematic. immunosuppressive drugs, such as azathioprine, are beneficial but may have serious side effects. therefore, new therapeutic approach is needed. prostaglandin e2 is one of the prostanoids, which is involved with innate immunity. pge2 induces oral tolerance to specific antigen in the small intestine and downregulates the production and release of proinflammatory cytokines by macrophages and neutrophils. accordingly, pge2 is considered to be the mediator of mucosal protection. recently, it was elucidated that disruption of ep4 gene, which is one of pge receptors, caused severe colitis in mice. moreover, ep4-selective agonist (ae1-734) was also revealed to ameliorate severe dextran sodium sulfate-induced colitis in mice. we therefore examined the effects of 2 weeks intravenous ep4-selective agonist therapy for patients with mild to moderate ulcerative colitis.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of ulcerative colitis 2. mild to moderate ulcerative colitis refractory to 5-aminosalicylates therapy. 3. 20 years and above 4. must obtain written informed consent exclusion criteria: 1. corticosteroids therapy within two weeks before enrollment 2. immunosuppressive therapy within three months before enrollment 3. leukocytapheresis therapy within one month before enrollment 4. blood transfusion within two weeks before enrollment 5. impaired renal function 6. impaired hepatic function 7. uncontrolled hypertension/hypotension 8. uncontrolled arrhythmia 9. impaired cardiac function 10. cancer 11. uncontrolled diabetes 12. interstitial pneumonia 13. glaucoma 14. history of colon resection 15. infectious diseases needing medical treatments 16. drug allergy 17. pregnancy

Keywords: ulcerative colitis ep4 agonist pge2
unknown glucose metabolism disorders in patients with coronary artery disease

Conditions: Diabetes Mellitus

Summary: this study aimed to examine the prevalence of glucose metabolism disorders (gmd)in the patients with coronary artery disease and the relationship between different gmds and coronary artery disease (cad).

context: there are more than 220 million people diagnosed with diabetes mellitus (dm) in the world. dm is a serious risk factor for coronary artery disease (cad). this study aimed to examine the prevalence of glucose metabolism disorders (gmd) in te patients with coronary artery disease and the relationship between different gmds and cad. settings: 230 patients with coronary artery disease and without any known gmds were included the study. coronary angiography was used to diagnose cad. patients were administered the 75 g oral glucose tolerance test (ogtt).

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease and who had no glucose metabolism disorders were included to study. exclusion criteria: * patients who had previous gmds, malignancies, chronic liver and kidney diseases, rheumatologic disorders, and a bmi higher than 35 kg/m2 were excluded from the study.

Keywords: ogtt coronary artery disease
proprioceptive neuromuscular facilitation combined with postural education in upper cross syndrome

Conditions: Upper Cross Syndrome

Summary: the aim of this study was to investigate the effectiveness of pnf and conventional neck stretching, combined with a postural education program in improving forward head posture in students with clinical signs and symptoms of ucs. the study included a sample of undergraduate gulf medical university students with clinical signs and symptoms of ucs. a total of 24 samples were divided into two groups of 12. group a received pnf pattern neck stretching and self-resisted neck pnf pattern, whereas group b received conventional neck stretches along with isometric strengthening of the neck muscles. both groups were given a common postural education program. the intervention duration was 5 days per week for 4 weeks.

collegiate students are prone to adopt slouched posture and develop muscular imbalance which is considered as a causative factor for the development of ucs. studies have shown that students in medical universities have a higher risk of developing ucs. even though pnf is considered to be simple and effective to improve inter and intramuscular coordination, its application to collegiate students with ucs is limited. application of pnf combined with postural education programs may benefit the students to reduce ucs-associated clinical problems such as reduced forward head posture, pain intensity and improving muscle strength etc. our current study might open the door of simple and effective management of ucs among collegiate students. therefore, our study was conducted to find out the effect of pnf and active muscle stretching, both in combination with postural education programs, on forward head posture of the students with upper crossed syndrome. objectives: ● to compare the effect of pnf with active muscle stretching, both in combination with postural education programs on forward head posture of students with upper cross syndrome.

Eligibility criteria:
inclusion criteria: * students of gulf medical university. * both genders. * age between 18 - 30 years. * presence of clinical signs and symptoms of ucs. * presence of fhp with cva of 49 degrees and below. exclusion criteria: * musculoskeletal disorder such as strain, sprain, scoliosis. * students participating in any other interventions. * nutritional deficiencies. * unwilling participate. * degenerative joint disorder * neurologically unstable individuals

Keywords: upper cross syndrome postural correction neck pain upper back pain neuromuscular facilitation
adjunctive neurovascular support for wide-neck aneurysm embolization and reconstruction

Conditions: Intracranial Aneurysms

Summary: this study is designed to evaluate the safety of the pulserider in patients undergoing treatment for bifurcation basilar or carotid terminus aneurysms.

primary endpoints: * safety: death or stroke in downstream territory to 180-days post-procedure * technical success: device placement success and ability to retain coils at the time of the index procedure * rate of aneurysm occlusion at day zero (0) and 180 days additional evaluations to 180-days and at 365-day follow up: * rate of aneurysm occlusion at 365 days * device movement or migration * stenosis * rate of incidence of new neurological deficits * complication rate (neurological and non-neurological)

Eligibility criteria:
inclusion criteria: * patient who presents with an angiographically confirmed, wide neck intracranial aneurysms located at a bifurcation of the basilar artery or carotid terminus artery * the target aneurysm is in a vessel with a diameter of 2.7 mm to 4.5 mm. * the patient is 18 years or older at the time of consent * the patient has signed the irb/ec approved informed consent form * in the opinion of the physician, placement of the pulserider is technically feasible and clinically indicated * subject has mental capacity and is willing and able to comply with protocol requirements and follow-up exclusion criteria: * unstable neurological deficit (condition worsening within the last 90 days) * subarachnoid hemorrhage (sah) within the last 60 days * irreversible bleeding disorder * mrs score ≥3 * patient has another aneurysm which, in the investigator's opinion, will require treatment within the follow up period (365 days) * platelet count \< 100 x 103 cells/mm3 * inability to tolerate, adverse reaction or contraindication to taking aspirin or clopidogrel * a history of contrast allergy that cannot be medically controlled * known allergy to nickel * relative contraindication to angiography (e.g., serum creatinine \> 2.5 mg/dl) * woman with child-bearing potential who cannot provide a negative pregnancy test * evidence of active infection * other conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events * evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 365-day follow-up period * extracranial stenosis greater than 50% in the parent artery requiring access to the lesion * intracranial stenosis greater than 50% in the treated vessel * extreme vessel tortuosity that prohibits appropriate control of the micro-guide wire and/or the pulserider delivery wire
clinical and neurobiological profile predictive of pejorative outcome of depression

Conditions: Depression

Summary: depression is a frequent disease which can be marked by therapeutic resistance. it is described as one of the most disabling disease with high cost for society. world health organization pointed out that 350 million people are suffering from depression in the world. this pathology is considered underdiagnosed, with inadequate care resources and stigmatization. there is a wide range of evidence in current literature that anxiety is one of the most important factors involved in biological mechanism of treatment resistance in depression. to date, there is a lack of knowledge on this topic. a better understanding of the role of anxiety in the maintenance of depressive state will allow to i) identify quickly and more accurately patients at risk of pejorative evolution and ii) develop specific therapeutics targeting this dimension which remain badly controlled with actual therapeutics.


Eligibility criteria:
inclusion criteria: * men and women older than 18 years-old; * suffering from a mood depressive episode ( according to dsm iv criteria), and-or mood depressive recurrent depression (unipolar or bipolar) (\<at stage 3 of thase and rush). treatment resistance will be assessed using thase an rush classification and measured with maudsley staging method (fekadu et al., 2009); * madrs score 15; * capacity for the patient to receive information on protocol; * patient who gave their consent to the protocol. exclusion criteria: * contra-indication to mri * patients under social protection or hospitalized without their consent * patients suffering from a psychiatric comorbidity such as: schizophrenia, schizo-affective disorder, personality disorder, actual addiction, anorexia-bulimia, obsessive-compulsive disorder; * patients suffering from severe intercurrent disease with health prognosis engaged; * patients suffering from neurological comorbidity such as: any neurodegenerative disorder (alzheimer disease, parkinson disease, lewy's body disease, multiple sclerosis), any intracranial expansive process. * patients with an history of severe cranial injury (with coma); * patients with abnormal cerebral mri.
improving end-of-life care by continuing medical education and electronic decision making support for general practitioners

Conditions: Chronic Obstructive Pulmonary Disease; Metastatic Cancer

Summary: background: optimizing the basic palliative care has been shown beneficial to patients in end-of-life care, the general practitioner (gp) having a pivotal role in the health care system, providing comprehensive and continued medical care. the aim of the study is to investigate the effect of a complex intervention in general practice on gps' awareness of and confidence in providing end-of-life care. method: a follow-up study among 404 general practices in central denmark region. the participating general practices will get the opportunity to receive education in palliative care and access to an electronic support, which provides advice on palliative care and an overview of the palliative population in each medical practice. the education and the support will focus on patients suffering from either metastatic cancer or chronic obstructive pulmonary disease (gold stage 4). the end-of-life care delivered by the gps to their deceased patients will be analysed, based on questionnaires to gps and register data related to the deceased patients before and after the intervention, . primary outcomes: place of death of deceased patients, time spent at home, and number of hospital admissions in the last three months of the patients' lives. secondary outcomes: number and kinds of contacts between gps and patients, use of relevant medicine and of the 'safety box'. finally gps' confidence concerning palliative care will be assessed in questionnaires.


Eligibility criteria:
inclusion criteria: working as general practitioner in the central region of denmark in 2013 and onwards - exclusion criteria: -

Keywords: palliative care continuing medical education general practitioner electronic decision support
determinants of bone and muscle quality and strength in obesity with and without diabetes

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Body Weight; Bone Diseases, Metabolic; Fractures, Bone; Osteoporotic Fractures; Osteoporosis; Quality of Life; Fall; Musculoskeletal Diseases

Summary: background: osteoporotic fractures are a major public health issue. they cause substantial disability, loss of autonomy, morbidity and excess mortality. diabetes is also associated with increased risk for falls and fractures through a direct impact of elevated blood glucose on the skeleton and on muscles. research project overview: the investigators propose a cross-sectional study that will involve 2 research centers in the province of quebec. the investigators will recruit 20 obese participants, without diabetes, who have not undergone bariatric surgery, for one-time measurements to be compared with baseline measurements (pre-surgery) from participants in the bariatric obese diabetic groups with type ii diabetes mellitus from the ongoing study bodi study (nct03455868). bone mineral density as well as muscle quality, strength and function will be evaluated at a single study visit. relevance: this data will permit the evaluation of the bone-muscle unit in patients with obesity with and without diabetes, and assess whether the presence and duration of diabetes impacts further on clinical and functional musculoskeletal outcomes (falls, fractures and mobility and strength) in this population. ages, if associated with muscle and bone deterioration, might become an easily accessible biomarker of musculoskeletal health in the clinical setting.


Eligibility criteria:
inclusion criteria: a) diabetic group * bmi \>=35 kg/m2 * clinical diagnosis of type 2 diabetes * use of oral hypoglycemic agents or insulin or 2 of the following tests confirming type 2 diabetes: hba1c \>=6.5%; fasting glucose \>=7.0 mm; 2-h glucose post 75g oral glucose tolerance test (ogtt) \>=11.1 mm) b) non-diabetic group: * bmi \>=35 kg/m2 * normoglycemia (hgba1c \<5.7% and fasting glucose \<5.6 nm) exclusion criteria: * bmi \>60 kg/m2 * clinical diagnosis of type 1 diabetes * disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance \<60 ml/min) * medication (e.g. gluccocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism * pregnancy * history of oesophageal, gastric, digestive or bariatric surgery * prosthesis that could interfere with interpretation of imaging data * chronic severe condition or illness precluding from participation in the project.

Keywords: advanced glycation end products advanced imaging mobility strength
comparative study of secondary prophylaxis for sbp

Conditions: Spontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites

Summary: the goal of this clinical trial is to learn if norfloxacin, nitazoxanide, and colistin work as secondary prophylactic agents for spontaneous bacterial peritonitis (sbp) in cirrhotic patients with ascites. it also aims to evaluate the safety and effectiveness of these treatments. the main questions it aims to answer are: are nitazoxanide and colistin as effective as norfloxacin in preventing recurrent sbp? what medical outcomes do participants experience when taking norfloxacin, nitazoxanide, or colistin? researchers will compare norfloxacin, nitazoxanide, and colistin to determine their effectiveness in preventing sbp recurrence in cirrhotic patients. participants will: be randomly assigned to receive either 400 mg norfloxacin daily, 500 mg nitazoxanide twice daily, or 15 ml colistin syrup three times daily (2.25 miu total per day). undergo regular blood tests and ascitic fluid analysis at discharge, 2 months, and 6 months post-treatment. be monitored for any side effects and recurrence of sbp.


Eligibility criteria:
inclusion criteria: success criteria: a ≥50% reduction in crp within 3 months is considered a positive response. * ascitic patients diagnosed with spontaneous bacterial peritonitis (sbp) by paracentesis. * ascitic fluid polymorphonuclear (pmn) cell count \> 250/mm³. * age 50 years to 80 years. * willing to provide informed consent. exclusion criteria: * pregnant or breastfeeding females. * history of allergic reactions to norfloxacin, nitazoxanide, or colistin. * patients with recurrent spontaneous peritonitis. * presence of gastrointestinal hemorrhage. * renal failure (creatinine \> 2 mg/dl or on dialysis). * presence of severe infection-related sequelae (e.g., persistent fever, abdominal discomfort, sepsis).
acute cardiovascular effects of cigarette smoking

Conditions: Smoking

Summary: twenty healthy smokers will be subjected to measurement of pulse, blood pressure, electrocardiogram (ecg) and echo at baseline and after smoking a cigarette. the measurements will be compare for any cardiovascular effects of a cigarette smoking on these parameters.

twenty male persons habituated to smoking (at least 5 cigarettes/day) will be recruited after an informed consent. healthy persons with no systemic illness will be included. after a history and a routine examination, subjects will be asked to abstain from smoking for 3 hours and then their pulse, bp, ecg and echo recorded. the measurements will be repeated after 15 min. and the average of these two taken as baseline readings. then, they will be asked to smoke a cigarette and the measurements taken again. special focus will be on doppler measures of left ventricular (lv) function. the measurements are repeated immediately and at 5,10 and 15 min. the data will be analyzed for any cardiovascular effects of smoking a cigarette. chi square test for proportions and t-test for means will be done. a p value \< 0.05 will be taken as significant.

Eligibility criteria:
inclusion criteria: * healthy male smokers (at least 5 cigarettes /day) \>18 years old. exclusion criteria: * any cardiac or respiratory or systemic illness,including hypertension.

Keywords: cigarette smoking cardiovascular effects 2d echocardiography doppler